Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain (DOLORES)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB, Inc. ( UCB BIOSCIENCES GmbH )
ClinicalTrials.gov Identifier:
NCT01744496
First received: December 5, 2012
Last updated: February 6, 2014
Last verified: February 2014

December 5, 2012
February 6, 2014
November 2012
December 2013   (final data collection date for primary outcome measure)
Change from Baseline to the End of the Maintenance Period in pain severity assessed using an 11-point Likert Pain Scale [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after an up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
An 11-Point Likert Scale will be used to assess patients' average daily pain.
Same as current
Complete list of historical versions of study NCT01744496 on ClinicalTrials.gov Archive Site
  • Percentage of Responders at the End of the Maintenance Period [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
    Responders are defined as patients experiencing a 2-Point ore more Reduction on an 11-Point Likert Pain Scale from Baseline to the End of the Maintenance Period.
  • Change from Baseline to the End of the Maintenance Period in the sum score of the 8-Item Parkinson's Disease Questionnaire (PDQ-8) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the combined score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living [ADL] subscale) and III (motor subscale) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the 7 domain scores of Classification of Pain in Parkinson's Disease [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the 7-Item Depression subscore of the Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the 7-Item Anxiety subscore of the Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Percentage of Responders at the End of the Maintenance Period [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
    Responders are defined as patients experiencing a 2-Point Reduction on an 11-Point Likert Pain Scale from Baseline to the End of the Maintenance Period.
  • Change from Baseline to the End of the Maintenance Period in the sum score of the 8-Item Parkinson's Disease Questionnaire (PDQ-8) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the combined score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living [ADL] subscale) and III (motor subscale) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the Total Score of Classification of Pain in Parkinson's Disease [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the 7-Item Depression subscore of the Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
  • Change from Baseline to the End of the Maintenance Period in the 7-Item Anxiety subscore of the Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks ± 5 days after up to 7 weeks Titration Period) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

This trial is being conducted to compare the impact of Rotigotine and Placebo on Chronic Pain associated with Parkinson's Disease among patients with advanced stages of the disease.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Advanced Idiopathic Parkinson's Disease
  • Drug: Rotigotine
    Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
    Other Name: (6S)-6-propyl-[2 (2 thienyl)ethyl]amino-5,6,7,8-tetrahydro-1-naphthalenol
  • Drug: Placebo
    Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
  • Experimental: Rotigotine
    Rotigotine Transdermal Patches
    Intervention: Drug: Rotigotine
  • Placebo Comparator: Placebo
    Placebo Transdermal Patches
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
January 2014
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has advanced idiopathic Parkinson's Disease associated chronic pain assessed by a Likert Pain Scale
  • Patient is taking Levodopa with a stable daily dose of at least 200 mg for at least 21 days prior to start
  • Hoehn and Yahr stage score of II to IV
  • Mini-Mental State Examination (MMSE) score ≥ 25
  • If an antidepressant drug is taken, the dose must be stable for at least 21 days

Exclusion Criteria:

  • Therapy with a Dopamine Agonist within 21 days prior to start
  • Discontinuation from previous Dopamine Agonist Therapy due to lack of efficacy
  • Therapy with Dopamine-modulating substances 21 days prior to start
  • Therapy with analgesics for the treatment for pain, unless the dose has been stable
  • Chronic alcohol or drug abuse
  • Medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study
  • Hypersensitivity to any components of the Investigational Medicinal Product (IMP) or comparative drugs
  • Atypical Parkinson's Disease Syndrome due to drugs
  • History of deep brain stimulation
  • Significant skin disease that would make transdermal drug use inappropriate
  • Electroconvulsive therapy within 12 weeks prior to start
  • Evidence of an Impulse Control Disorder
  • Previous diagnosis of severe Restless Legs Syndrome
  • Chronic Migraine
  • Severe Depression
  • Symptomatic Orthostatic Hypotension
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Germany,   Poland,   Slovakia
 
NCT01744496
PD0004, 2012-002608-42
No
UCB, Inc. ( UCB BIOSCIENCES GmbH )
UCB BIOSCIENCES GmbH
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB, Inc.
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP